SCHEMBL23218824

SCHEMBL23218824

COCCC(=O)C(C(=O)OC)c1cc(Br)ccc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
DRD2 P14416 1/20 0.36
HPGD P15428 2/20 0.35
ALDH1A1 P00352 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
ALPL P05186 1/20 0.33
CYSLTR2 Q9NS75 1/20 0.33
CYSLTR1 Q9Y271 1/20 0.33
HTT P42858 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
APLNR P35414 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591689 1.00 KDM4E (0.36) KDM4ERAB9AKMT2ANPC1LMNA
SCHEMBL23218358 0.84 DRD2 (0.36) KDM4ERAB9ANPC1LMNASMN1; SMN2
SCHEMBL2402387 0.81 APLNR (0.35) KDM4EKMT2ASMN1; SMN2DRD2HPGD
SCHEMBL23218548 0.80 HPGD (0.40) KDM4ERAB9AKMT2ANPC1LMNA
SCHEMBL2401781 0.69 DRD2 (0.43) KDM4ERAB9AKMT2ALMNASMN1; SMN2
SCHEMBL25373748 0.66 PTGDR2 (0.54) KDM4EKMT2ASMN1; SMN2DRD2HPGD
SCHEMBL2863699 0.65 MEN1 (0.40) KDM4EKMT2ASMN1; SMN2DRD2HPGD
SCHEMBL4816617 0.65 DRD2 (0.45) KDM4ERAB9ANPC1SMN1; SMN2DRD2
SCHEMBL941194 0.65 DRD2 (0.40) KDM4ERAB9ANPC1SMN1; SMN2DRD2
SCHEMBL5715655 0.64 ELANE (0.43) RAB9ALMNADRD2ALDH1A1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KDM4E 4172/4885RAB9A 1922/4885KMT2A 4445/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KDM4E 4491/4885RAB9A 1852/4885KMT2A 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.